Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapy

Reports

3

Domains carrying it

3

First reported

21 August 2026

Latest report

2 September 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 21 August 2026Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapyallsci.com
2. 24 August 2026Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdictfiercepharma.com
3. 2 September 2026Hansa CEO Aguiar-Lucander: U.S. Listing Is Not Optional for European Biotechfinance.biggo.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Capricor soars on potential FDA review extension, filing amendments9 reports · 6 domains · 25 August 2026
• Small US biotechs cite FDA barriers to first-in-human trials: survey3 reports · 3 domains · 12 August 2026
• FDA panel to review popular peptides amid persistent consumer appetite13 reports · 12 domains · 31 July 2026
• Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA ...2 reports · 2 domains · 24 August 2026
• America's Next Biotech Challenge2 reports · 1 domains · 6 August 2026
• U.S. Rare Disease Biotech Investing Rises After FDA's PRV Program Renewal: Report2 reports · 2 domains · 11 August 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• Hansa CEO Aguiar-Lucander: U.S. Listing Is Not Optional for European Biotechfinance.biggo.com · 2 September 2026
• Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdictfiercepharma.com · 24 August 2026
• Hansa aims for secondary US listing ahead of FDA decision on kidney transplant therapyallsci.com · 21 August 2026